A finding that could help Alpha-1 sufferers breathe more easily

A finding that could help Alpha-1 sufferers breathe more easily

Garvan researchers in collaboration with colleagues in the US have identified a new mutation in the gene that causes the inherited disease known as Alpha-1 Antitrypsin Deficiency (Alpha-1), which affects roughly one in 2,500 people of European descent. Alpha-1 can lead to serious lung disease in adults, or liver disease at any age. The finding extends understanding of Alpha-1 at the molecular level, potentially leading to new drug development and better diagnostic tools.
A finding that could help Alpha-1 sufferers breathe more easily
Media Release: 14 December 2012

Scientists have identified a new mutation in the gene that causes the inherited disease known as Alpha-1 Antitrypsin Deficiency (Alpha-1), which affects roughly one in 2,500 people of European descent.

Alpha-1 can lead to serious lung disease in adults, or liver disease at any age.

The finding extends understanding of Alpha-1 at the molecular level, potentially leading to new drug development and better diagnostic tools.

Dr Darren Saunders from Sydney’s Garvan Institute of Medical Research and Professor Vanessa Hayes, from the J. Craig Venter Institute in San Diego, published their results in the international journal PLOS One, now online.

In healthy people, Alpha-1 Antitrypsin is a molecule, or ‘protein’, made in the liver then secreted into the blood. It helps keep the lungs healthy by blocking an enzyme that causes tissue breakdown.

The genetic mutations that trigger Alpha-1 disease cause the Alpha-1 Antitrypsin protein to accumulate in the liver, rather than being secreted into the blood. That in turn leads to tissue breakdown in the lungs.

Alpha-1 is often first diagnosed as asthma or smoking-related Chronic Obstructive Pulmonary Disease (COPD). Typically, people experience symptoms like shortness of breath, wheezing, recurrent chest colds and allergies. They might also develop unexplained liver disease.

“We’re interested in the fact that the mutation we’ve identified occurs in a completely different part of the gene from known mutations, yet it causes the same basic effect – the protein doesn’t get secreted from liver cells,” said Dr Saunders.

The research is still early stage, as the mutation has been identified in only one patient, and that patient is from a Middle-Eastern background.

“We have yet to establish the mutation’s prevalence, and we can’t do that until we have the funding to examine a wider population of patients.

“At the basic science level, it’s a promising breakthrough because it helps us better understand how the protein misbehaves when it’s mutated – and that’s very important for drug development, because drugs have to try and minimise, or reverse, molecular damage.

“If the mutation turns out to be prevalent, then its inclusion in diagnostic tests will be important.”


ABOUT GARVAN
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with over 600 scientists, students and support staff. Garvan's main research areas are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology and Neuroscience. Garvan's mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan's discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.

 

All media enquiries should be directed to:
Alison Heather

Science Communications Manager

M: + 61 434 071 326

P: +61 2 9295 8128

E: a.heather "a" garvan.org.au